Thank you Zake. Good read. It was nothing new to me but it was a good current status summary. What has really sparked my interest is in the non CF market after we get to second base. Not much is being said about this except that Insmed will decide what path to take after the second trail is completed in the 4th qtr. I think the market for non CF treatment is huge. 500,000 in the US. How many in Europe? How many worldwide? Mr. Lewis is a sharp cookie. We will all know soon enough. Also, good call on your part back in April on the rise to $13.00.
The key points.
"When it comes to investing in young and unproven biotech stocks, you want to look for a few key characteristics. First, the company should be targeting a market for which current treatments are less than ideal. Second, this potential market should be fairly large in size and scope. And third, you want to focus on companies that have already established compelling, robust results in clinical testing trials.
New Jersey-based Insmed (INSM) checks all those boxes. Better still, a clear imminent catalyst exists to send this stock to fresh highs."